Dinuclear Copper(II) complexes of Fenoprofen with nitrogenated ligands: synthesis, spectroscopic, thermal and SOD-mimic activity studies

AGOTEGARAY, MARIELA; BOERIS, MÓNICA; DIEZ, ALEJANDRA; PRAT, MARÍA ROSA; QUINZANI, OSCAR

JOURNAL OF COORDINATION CHEMISTRY

TAYLOR & FRANCIS LTD

Lugar: Londres; Año: 2011 vol. 64 p. 2246 - 2261

0095-8972

Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- phenoxyphenyl)propionic acid] and nitrogen donors of general formula [Cu2(fen)4(L)]n were prepared from [Cu2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of prepared from [Cu2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of prepared from [Cu2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of 2(fen)4(L)]n were prepared from [Cu2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of 2(fen)4(dmf)2]2H2O (1) [dmf¼N,N0-dimethylformamide; L¼4,40-bipyridine (2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of 2), pyrazine (3), and 2,5-dimethylpyrazine (4)]. The new complexes were characterized by chemical analysis, spectroscopic, and thermogravimetric techniques. Antioxidant properties of 1–4 were evaluated for superoxide-dismutase-mimic activity employing the XTT method. Complex 2 presented the highest antioxidant activity (IC50¼0.260 mmol L1). Anti-inflammatory properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- Complex 2 presented the highest antioxidant activity (IC50¼0.260 mmol L1). Anti-inflammatory properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- Complex 2 presented the highest antioxidant activity (IC50¼0.260 mmol L1). Anti-inflammatory properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- were evaluated for superoxide-dismutase-mimic activity employing the XTT method. Complex 2 presented the highest antioxidant activity (IC50¼0.260 mmol L1). Anti-inflammatory properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- properties of 2 were evaluated employing carrageenan-induced paw edema in mice, revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- revealing that the Fenoprofen–copper(II) complex containing 4,40-bipyridine does not present enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II) complexes with the anti-inflammatory drug Fenoprofen [Hfen, 2-(3- enhanced anti-inflammatory activity compared to the uncomplexed parent drug Fenoprofen calcium salt. Three dinuclear copper(II